PT  - JOURNAL ARTICLE
AU  - SHOZO IDE
AU  - YUJI TOIYAMA
AU  - YOSHINAGA OKUGAWA
AU  - SATOSHI OKI
AU  - HIROMI YASUDA
AU  - HIROYUKI FUJIKAWA
AU  - SHIGEYUKI YOSHIYAMA
AU  - JUNITIRO HIRO
AU  - MINAKO KOBAYASHI
AU  - MASAKI OHI
AU  - TOSHIMITSU ARAKI
AU  - MASATO KUSUNOKI
TI  - Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery
DP  - 2017 Oct 01
TA  - Anticancer Research
PG  - 5797--5804
VI  - 37
IP  - 10
4099  - http://ar.iiarjournals.org/content/37/10/5797.short
4100  - http://ar.iiarjournals.org/content/37/10/5797.full
SO  - Anticancer Res2017 Oct 01; 37
AB  - Background/Aim: This study was designed to evaluate the clinical significance of the C-reactive protein-to-albumin ratio (CAR) in patients with rectal cancer undergoing preoperative chemoradiotherapy (CRT) followed by surgery. Patients and Methods: This retrospective study evaluated the correlation between CAR and prognosis in 115 patients with locally advanced rectal cancer. We also carried out subgroup analyses limited to patients with low modified Glasgow prognosis score (mGPS) (score 0) or pathological TNM stage I-II [ypN(−)]. Results: CAR exhibited significant relationships with sex, tumor invasion, recurrence, serum carcinoembryonic antigen, and mGPS. Elevated CAR was an independent prognostic factor for overall survival (OS) and disease-free survival (DFS) among all patients. Elevated CAR also predicted poor OS and DFS in patients with pathological TNM stage I-II [ypN(−)] and low mGPS score. Conclusion: CAR is a promising predictor of survival and recurrence in patients with rectal cancer treated by CRT.